We observed a lower proportion of tumor-associated macrophages expressing the inhibitory molecules PD-L1+, PD-L2+ and B7-H4+ at surgery in comparison to baseline in patients from Group 1A. The gene discussed is VTCN1; the disease is neoplasm.